Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
China Just Got A Lot Closer To Its First-Ever Manned Moon Landing - 2The teen queen bee of 'Laguna Beach' is now a 'cringey' mom
- 3Electric discovery on Mars! Scientists find tiny lightning bolts coming from Red Planet dust clouds
- 4Analysis-From 'Icarus bug' to flawed panels: Airbus counts cost of relying on single model
- 5A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
- Vote in favor of your #1 Sort of Convenience for a Family
- Instructions to Augment the Presentation of Your Kona SUV
- Trying to improve your health and wellness in 2026? Keep it simple
- As juries turn against social media for harming kids, Big Tech's invincibility starts to show cracks
- Italy Brings In New Measures In 2026 To Tackle Overtourism
- Apartment Turned Into Nightmare 'Ice Castle' After Tenant Shut Off Heat Causing Pipes to Burst: VIDEO
- Top notch Feasting: A Manual for Worldwide Acclaimed Eateries
- The Best Competitors of the 21st Hundred years
- Research institutions tout the value of scholarship that crosses disciplines – but academia pushes interdisciplinary researchers out
